Page 864 - Read Online

Silk et al. Hepatoma Res 2020;6:73 I http://dx.doi.org/10.20517/2394-5079.2020.61 Page 15 of 16

Am Acad Dermatol 2014;71:217.e1-11; quiz 227-8.
9. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol
2008;47:176-86.
10. Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, et al. Development and validation of a prediction index for hand-foot skin reaction in
cancer patients receiving sorafenib. Ann Oncol 2012;23:2103-8.
11. Cheng A, Kang Y, Chen Z, Tsao C, Qin S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
12. Zhang HL, Qin XJ, Wang HK, Gu WJ, Ma CG, et al. Clinicopathological and prognostic factors for long-term survival in Chinese
patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Oncotarget 2015;6:36870-83.
13. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib
and sunitinib. Oncology 2009;77:257-71.
14. McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand-foot skin reaction: practical advice on
diagnosis, prevention, and management. Ann Oncol 2015;26:2017-26.
15. Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, et al. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor
cabozantinib. JAMA Dermatol 2015;151:170-7.
16. Reed N, Glen H, Gerrard G, Good J, Lei M, et al. Expert consensus on the management of adverse events during treatment with
lenvatinib for thyroid cancer. Clin Oncol (R Coll Radiol) 2020;32:e145-53.
17. Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar
erythrodysesthesia syndrome? Ann Oncol 2005;16:1210-1.
18. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, et al. Evolving strategies for the management of hand-foot skin reaction
associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001-11.
19. Ai L, Xu Z, Yang B, He Q, Luo P. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention,
and management. Expert Rev Clin Pharmacol 2019;12:1121-7.
20. Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, et al. Search for evidence-based approaches for the prevention and palliation of
hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009;14:291-302.
21. Ren Z, Zhu K, Kang H, Lu M, Qu Z, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-
associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33:894-900.
22. Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a clinician's perspective. Semin Oncol
2014;41 Suppl 2:S1-16.
23. Common Terminology Criteria for Adverse Events (CTCAE) v5. US Department of health and human services. National Institute
of Health. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_
Reference_5x7.pdf. [Last accessed on 30 Sep 2020]
24. Vukelja SJ, Lombardo FA, James WD, Weiss RB. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med
1989;111:688-9.
25. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib
and sunitinib. Ann Oncol 2008;19:1955-61.
26. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase
inhibitor. Arch Dermatol 2008;144:886-92.
27. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase
inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161:1045-51.
28. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, et al. Incidence and timing of common adverse events in Lenvatinib-
treated patients from the SELECT trial and their association with survival outcomes. Endocrine 2017;56:121-8.
29. Wood LS. Managing the side effects of sorafenib and sunitinib. Commun Oncol 2006;3:558-62.
30. Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, et al. HER1/EGFR inhibitor-associated rash: future directions for management
and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-56.
31. Sarkodie T, Ross P. Late presentation of sorafenib-associated rash: a case report. J Med Case Rep 2010;4:338.
32. Çalışkan S. Sorafenib-induced Scrotal Eczema. Rev Urol 2015;17:250-1.
33. Ishak RS, Aad SA, Kyei A, Farhat FS. Cutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF
inhibitors. Crit Rev Oncol Hematol 2014;90:152-64.
34. De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, et al. Prevention and management of adverse events related to
regorafenib. Support Care Cancer 2014;22:837-46.
35. Harris DJ, Eilers J, Harriman A, Cashavelly BJ, Maxwell C. Putting evidence into practice: evidence-based interventions for the
management of oral mucositis. Clin J Oncol Nurs 2008;12:141-52.
36. Bensinger W, Schubert M, Ang KK, Brizel D, Brown E, et al; NCCN Task Force Report. Prevention and management of mucositis in
cancer care. J Natl Compr Canc Netw 2008;6 Suppl 1:S1-21.
37. Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, et al. Expert consensus on the management of adverse events from EGFR
tyrosine kinase inhibitors in the UK. Drugs 2015;75:1335-48.
38. Bayer HealthCare Pharmaceuticals Inc. Nexavar (Sorafenib) [package insert]. U.S. Food and Drug Administration website. Available
from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf. [Last accessed on 24 Sep 2017]
39. Guggina LM, Choi AW, Choi JN. EGFR inhibitors and cutaneous complications: a practical approach to management. Oncol Ther